Download MendeleyDiscovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH).
Rai, G., Brimacombe, K.R., Mott, B.T., Urban, D.J., Hu, X., Yang, S.M., Lee, T.D., Cheff, D.M., Kouznetsova, J., Benavides, G.A., Pohida, K., Kuenstner, E.J., Luci, D.K., Lukacs, C.M., Davies, D.R., Dranow, D.M., Zhu, H., Sulikowski, G., Moore, W.J., Stott, G.M., Flint, A.J., Hall, M.D., Darley-Usmar, V.M., Neckers, L.M., Dang, C.V., Waterson, A.G., Simeonov, A., Jadhav, A., Maloney, D.J.(2017) J Med Chem 60: 9184-9204
- PubMed: 29120638
- DOI: https://doi.org/10.1021/acs.jmedchem.7b00941
- Primary Citation of Related Structures:
5W8H, 5W8I, 5W8J, 5W8K, 5W8L - PubMed Abstract:
We report the discovery and medicinal chemistry optimization of a novel series of pyrazole-based inhibitors of human lactate dehydrogenase (LDH). Utilization of a quantitative high-throughput screening paradigm facilitated hit identification, while structure-based design and multiparameter optimization enabled the development of compounds with potent enzymatic and cell-based inhibition of LDH enzymatic activity. Lead compounds such as 63 exhibit low nM inhibition of both LDHA and LDHB, submicromolar inhibition of lactate production, and inhibition of glycolysis in MiaPaCa2 pancreatic cancer and A673 sarcoma cells. Moreover, robust target engagement of LDHA by lead compounds was demonstrated using the cellular thermal shift assay (CETSA), and drug-target residence time was determined via SPR. Analysis of these data suggests that drug-target residence time (off-rate) may be an important attribute to consider for obtaining potent cell-based inhibition of this cancer metabolism target.
Organizational Affiliation:
National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
